Spero Therapeutics, Inc.SPRONASDAQ
LOADING
|||
Switch Symbol:
Net Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year net income growth rate
Latest
-334.24%
↓ 1027% below average
Average (36q)
36.04%
Historical baseline
Range
High:1697.22%
Low:-334.24%
Volatility
5636.3%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -334.24% |
| Q2 2025 | 87.74% |
| Q1 2025 | 33.62% |
| Q4 2024 | -21.82% |
| Q3 2024 | 4.00% |
| Q2 2024 | -40.99% |
| Q1 2024 | -124.75% |
| Q4 2023 | 1697.22% |
| Q3 2023 | 73.10% |
| Q2 2023 | 10.19% |
| Q1 2023 | -149.55% |
| Q4 2022 | 329.30% |
| Q3 2022 | 59.30% |
| Q2 2022 | 12.63% |
| Q1 2022 | -12.27% |
| Q4 2021 | -29.83% |
| Q3 2021 | -21.26% |
| Q2 2021 | 4.38% |
| Q1 2021 | -4.51% |
| Q4 2020 | 1.85% |
| Q3 2020 | -8.20% |
| Q2 2020 | 24.75% |
| Q1 2020 | 6.92% |
| Q4 2019 | -41.03% |
| Q3 2019 | -34.73% |
| Q2 2019 | -159.27% |
| Q1 2019 | 52.15% |
| Q4 2018 | -1.30% |
| Q3 2018 | -5.09% |
| Q2 2018 | 6.46% |
| Q1 2018 | 27.94% |
| Q4 2017 | -50.16% |
| Q3 2017 | -7.27% |
| Q2 2017 | -56.04% |
| Q1 2017 | 18.51% |
| Q4 2016 | -14.17% |
| Q3 2016 | 0.00% |